Does injection location matter for a new Weight-Loss drug? a trial investigates
NCT ID NCT07725809
First seen Jul 24, 2026 · Last updated Jul 24, 2026
Summary
This early-stage trial is testing how an experimental drug called PF-08653945 enters the bloodstream when injected into different areas of the body. Researchers will give a single dose to adults who are overweight or obese and measure drug levels in the blood over time. The goal is to understand whether the injection site affects how much drug gets absorbed, which could guide how the medicine is given in future studies. Safety and side effects will also be tracked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental drug called PF-08653945 given as a single injection under the skin
- What this could lead to
- If successful, this study could help determine the best injection site for future trials of this experimental weight-loss drug.
- What could go wrong
- This is a very early phase 1 trial with only 57 participants, so results may not predict how the drug works in larger, more diverse groups. The main goal is measuring drug levels, not weight loss or long-term safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pfizer Clinical Research Unit - Brussels
Brussels, Bruxelles-capitale, Région de, B-1070, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Timing your meals or halving your rice: a new trial tests simple diet hacks for weight loss and blood sugar control
- Can a new drug boost Semaglutide's power against diabetes and obesity?
- Can a Normal-Weight baseline improve heart risk assessment in type 1 diabetes?
- A daily pill for obesity? zenagamtide faces its biggest test yet.
- Dance and walking may boost heart health in obesity — a trial puts it to the test
- Which medical adhesive stays put longest without itching? a head-to-head test in healthy women.